Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)

NCT01071954 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01071954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01071954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
December 30, 2009
Completion date
January 12, 2017
Enrollment
66 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

thrombocytopenia in pediatric subjects with immune idiopathic thrombocytopenic purpura itp